Opko Health OPK Pharmaceutical — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Opko Health in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opko Health's pharmaceutical — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opko Health's pharmaceutical — operating income?
- Opko Health (OPK) reported pharmaceutical — operating income of -$29.68M in Q1 2026.
- How has Opko Health's pharmaceutical — operating income changed year-over-year?
- Opko Health's pharmaceutical — operating income increased by 14.6% year-over-year, from -$34.77M to -$29.68M.
- What is the long-term trend for Opko Health's pharmaceutical — operating income?
- Over 3 years (2021 to 2025), Opko Health's pharmaceutical — operating income has grown at a 72.9% compound annual growth rate (CAGR), from -$19.04M to -$98.34M.
- What does pharmaceutical — operating income mean?
- The profit or loss generated by the pharmaceutical segment after accounting for all operating revenues and expenses, including production costs, R&D, and administrative overhead. It serves as the primary measure of the segment's operational performance and financial health.